Abstracts Archive - Page 2262 of 2425 - ACR Meeting Abstracts

Abstract Number: 2420 • 2012 ACR/ARHP Annual Meeting
Frequent Self-Reported Pain and Disease Symptoms in Juvenile Idiopathic Arthritis Persist Despite Advances in Medication Therapies: An Electronic Diary Study
Maggie H. Bromberg¹, Mark Connelly², Kelly K. Anthony³, Karen M. Gil¹ and Laura E. Schanberg⁴, ¹Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Integrative Pain Management, Children's Mercy Hospitals and Clinics, Kansas City, MO, ³Medical Psychology, Duke University Medical Center, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC
Background/Purpose: Previous research has demonstrated that children with Juvenile Idiopathic Arthritis (JIA) experience frequent pain that interferes with performing tasks at home and at school.…
Abstract Number: 2421 • 2012 ACR/ARHP Annual Meeting
The Pediatric Rheumatology Nursing Network: An International Email MANAGED COMMUNICATION System
Norma L. Liburd, Rheumatology, All Children's Hospital, St. Petersburg, FL
Background/Purpose: The Pediatric Rheumatology Nursing (PRN) Network is an electronic listserv linking 190 pediatric rheumatology nurses in 8 countries. Pediatric rheumatology nurses often have a sense…
Abstract Number: 2422 • 2012 ACR/ARHP Annual Meeting
Sexual Activity and Sexual Functioning Among Women with Systemic Sclerosis Compared to Women From a Population Sample
Brooke Levis¹, Andrea Burri², Marie Hudson³, Murray Baron⁴ and Brett D. Thombs⁵, ¹Epidemiology, McGill University, Montreal, QC, Canada, ²Twin Research and Genetic Epidemiology, King's College, London, United Kingdom, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁵Psychiatry, McGill University, Montreal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a chronic, multi-system, connective tissue disorder characterized by thickening and fibrosis of the skin and internal organ involvement.…
Abstract Number: 2423 • 2012 ACR/ARHP Annual Meeting
Perceptions Regarding Cardiovascular Risk Factors and Barriers to Risk Reduction Among African American Women with Lupus
Barron Mia¹, Lynne Nemeth¹, Diane L. Kamen² and Youlanda C. Gibbs¹, ¹College of Nursing, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Cardiovascular disease (CVD) is highly prevalent among African American (AA) women diagnosed with systemic lupus erythematosus (SLE). Studies have suggested that CVD risk factors…
Abstract Number: 2424 • 2012 ACR/ARHP Annual Meeting
Sleep Disturbances in Systemic Sclerosis: Evidence for the Role of Gastrointestinal Symptoms, Pain, and Pruritus
Katherine Milette¹, Marie Hudson², Annett Koerner¹, Murray Baron³ and Brett D. Thombs⁴, ¹Educational and Counselling Psychology, McGill University, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Psychiatry, McGill University, Montreal, QC, Canada
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune connective tissue disorder characterized by thickening and fibrosis of the skin and internal organs. There is significant mortality…
Abstract Number: 2425 • 2012 ACR/ARHP Annual Meeting
A Qualitative Study of Self-Image and Body Image in Individuals with Systemic Lupus Erythematosus
Afton L. Hassett¹, Diane C. Radvanski² and Elizabeth Hale³, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Department of Rheumatology, Dudley Group NHS Foundation Trust, Dudley, United Kingdom
Background/Purpose: Symptoms and treatment related to SLE are often outwardly evident. Patients with SLE cope with such external manifestations as joint swelling, rashes, scarring, loss…
Abstract Number: 2385 • 2012 ACR/ARHP Annual Meeting
Prognostic Impact of HLA-B^*51 and HLA–A^*26:01 On Ocular Behcet’s Disease
Jun Won Park¹, Eun Ha Kang², Hye Won Kim¹, Chaerin Park³, Hyeong Gon Yu³, Eun Young Lee¹, Yun Jong Lee⁴, Eun Bong Lee¹ and Yeong Wook Song⁵, ¹Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Ophthalmology, Seoul National University Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: To investigate the prognostic implication of HLA-B*51 and HLA-A*26:01on visual outcome in Korean Behcet’s disease (BD) patients with uveitis. Methods: Seventy-seven Korean BD patients…
Abstract Number: 2386 • 2012 ACR/ARHP Annual Meeting
Disability and Mortality Related to Cerebrovascular Disease in Systemic Vasculitis
Jamal Mikdashi¹ and Marcia Wozniak², ¹Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Department of Neurology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Despite improved therapeutic strategies, patients with systemic vasculitis (SV) continue to experience serious morbidity and mortality from persistent low grade disease activity and permanent…
Abstract Number: 2387 • 2012 ACR/ARHP Annual Meeting
Takayasu’s Arteritis: Features and Management of 216 Patients in China
Xia Liu¹, Tao Zhang², Xiaofeng Zhuang³, Kai Yuan¹, Xiaoming Shu¹ and Guochun Wang¹, ¹Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ²Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China, ³Department of Cardiology, FuWai Hospital and Cardiovascular Institute, Beijing, China
Background/Purpose: Takayasu’s arteritis (TA) is a rare vasculitis. Although it appears to be most common in Asia countries, research on Chinese TA patients with large…
Abstract Number: 2388 • 2012 ACR/ARHP Annual Meeting
Urticarial Vasculitis: Clinical Study
Javier Loricera¹, Vanesa Calvo-Rio², Francisco Ortiz Sanjuan², Marcos Antonio Gonzalez-Lopez³, Hector Fernandez-Llaca³, Javier Rueda-Gotor², Carmen Gonzalez-Vela⁴, Cristina Mata-Arnaiz⁵, Jose Luis Peña-Sagredo², Miguel A. Gonzalez-Gay² and Ricardo Blanco², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁴Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Rheumatology, Hospital Laredo, Santander, Spain
Background/Purpose: Urticarial vasculitis is an infrecuent subset of vasculitis described by McDuffy et al, in 1973, characterized clinically by urticarial skin lesions of more than…
Abstract Number: 2389 • 2012 ACR/ARHP Annual Meeting
Cutaneous Leukocytoclastic Angiitis: Study of 173 Patients
Javier Loricera¹, Vanesa Calvo-Rio¹, Francisco Ortiz-Sanjuan¹, Marcos Antonio Gonzalez-Lopez², Hector Fernandez-Llaca³, Javier Rueda-Gotor⁴, Carmen Gonzalez-Vela⁵, Miguel A. Gonzalez-Gay⁴ and Ricardo Blanco⁴, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Cutaneous leukocytoclastic angiitis (CLA) was defined by the International Consensus Conference for the Nomenclature of the Vasculitis (Chapel Hill, A&R 1994) as an isolated…
Abstract Number: 2390 • 2012 ACR/ARHP Annual Meeting
Color Doppler Ultrasonography an Alternative to CT/MR Angiography for Identifying Large Vessel Involvement in Giant Cell Arteritis?
Andreas P. Diamantopoulos¹, Glenn Haugeberg¹ and Geirmund Myklebust², ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Hospital of Southern Norway, Kristiansand, Norway
Background/Purpose: Large vessel involvement has been reported to be present in 20-50% of patients with giant cell arteritis (GCA). Computed tomography (CT) and magnetic resonance…
Abstract Number: 2391 • 2012 ACR/ARHP Annual Meeting
New Disease Manifestations After Diagnosis in Six Types of Vasculitis
Peter C. Grayson¹, David Cuthbertson², Simon Carette³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Kathleen Maksimowicz-McKinnon⁸, Paul A. Monach⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Steven R. Ytterberg¹² and Peter A. Merkel¹³, ¹Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Div of Rheum/E1-422, UHN/MSH, Toronto, ON, Canada, ⁴Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Boston University, Boston, MA, ¹⁰Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology Division, Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The proportion of patients who experience new manifestations of vasculitis after diagnosis is unknown. Our objectives were to quantify the occurrence of new…
Abstract Number: 2392 • 2012 ACR/ARHP Annual Meeting
Blood Vessel Instability and Oxidative Damage in Giant Cell Arteritis
Danielle Molloy¹, Jennifer McCormick², Mary Connolly², Muhammad Haroon³, Douglas J. Veale², Conor Murphy⁴, Ursula Fearon² and Eamonn S. Molloy¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ²Rheumatology, Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, ³Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis is incompletely understood, but involves neoangiogenesis and inflammatory infiltration of…
Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins
Alexandre Wagner S. de Souza¹, Karina de Leeuw², Johanna Westra², Andries J. Smit³, Anne Marijn van der Graaf², Hans L. A. Nienhuis¹, Johan Bijzet², Pieter C. Limburg⁴, Coen A. Stegeman⁵, Marc Bijl⁶ and Cees G.M. Kallenberg², ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁵Nephrology, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].